Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 5/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25830882 | 1.00 | JAK2 (0.55) | JAK2BTKTLR9TLR8TLR7 | |
| SCHEMBL31188129 | 0.84 | BTK (0.49) | JAK2BTKWNT3ASYK | |
| SCHEMBL31017624 | 0.77 | DDB1 (0.49) | JAK2BTKTLR9TLR8TLR7 | |
| SCHEMBL25830951 | 0.77 | DDB1 (0.49) | JAK2BTKTLR9TLR8TLR7 | |
| SCHEMBL25831131 | 0.76 | PDE4B (0.50) | JAK2BTKTLR9TLR8TLR7 | |
| SCHEMBL31017634 | 0.76 | PDE4B (0.50) | JAK2BTKTLR9TLR8TLR7 | |
| SCHEMBL31017628 | 0.72 | PDE4B (0.50) | JAK2BTKTLR9TLR8TLR7 | |
| SCHEMBL25831121 | 0.72 | PDE4B (0.50) | JAK2BTKTLR9TLR8TLR7 | |
| SCHEMBL19092554 | 0.71 | NAMPT (0.50) | JAK2TLR7WNT3ADDB1CRBN | |
| SCHEMBL25258405 | 0.71 | GPR119 (0.49) | JAK2TLR7WNT3AGPR119HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| CN-118414336-A | Degradation of Bruton Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2024-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | JAK2 185/4885BTK 1/4885TLR9 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.